ImmunityBio, Inc.
NASDAQ: IBRX
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shi
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
US Equity Report
A$5000.00
Already a subscriber?
Sign in to read this report.
Required subscription
US Equity Report
Expand beyond the ASX with expert research on carefully selected U.S. stocks, covering market leaders, emerging opportunities, and global investment trends.
- ✓ U.S. Stock Research & Analysis
- ✓ Delivered every Friday
- ✓ Company & Industry Analysis
- ✓ Full Historical Report Access
A$5000.00/ 12 months
Risk:Medium
Subscribe Now →
